Motley Fool Money cover image

Amazon Up, Walgreens, Nike & McPlant Down

Motley Fool Money

00:00

The Disruption Dilemma: Weight Loss Drugs and Sleep Apnea Treatments

This chapter explores the effects of weight loss drugs like Eli Lilly's ZepBound on the medical technology sector, especially regarding sleep apnea treatments. It highlights the market fluctuation for ResMed and raises questions about the future of GLP-1 drugs in healthcare.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app